000151138 001__ 151138 000151138 005__ 20250227101503.0 000151138 0247_ $$2doi$$a10.3390/pharmaceutics13091382 000151138 0248_ $$2sideral$$a125820 000151138 037__ $$aART-2021-125820 000151138 041__ $$aeng 000151138 100__ $$0(orcid)0000-0001-5201-0874$$aRedrado M. 000151138 245__ $$aDual emissive ir(Iii) complexes for photodynamic therapy and bioimaging 000151138 260__ $$c2021 000151138 5060_ $$aAccess copy available to the general public$$fUnrestricted 000151138 5203_ $$aPhotodynamic therapy (PDT) is a cancer treatment still bearing enormous prospects of improvement. Within the toolbox of PDT, developing photosensitizers (PSs) that can specifically reach tumor cells and promote the generation of high concentration of reactive oxygen species (ROS) is a constant research goal. Mitochondria is known as a highly appealing target for PSs, thus being able to assess the biodistribution of the PSs prior to its light activation would be crucial for therapeutic maximization. Bifunctional Ir(III) complexes of the type [Ir(CˆN)2 (NˆN-R)]+, where NˆC is either phenylpyridine (ppy) or benzoquinoline (bzq), NˆN is 2, 2'-dipyridylamine (dpa) and R either anthracene (1 and 3) or acridine (2 and 4), have been developed as novel trackable PSs agents. Activation of the tracking or therapeutic function could be achieved specifically by irradiating the complex with a different light wavelength (405 nm vs. 470 nm respectively). Only complex 4 ([Ir(bzq)2(dpa-acr)]+) clearly showed dual emissive pattern, acridine based emission between 407–450 nm vs. Ir(III) based emission between 521 and 547 nm. The sensitivity of A549 lung cancer cells to 4 evidenced the importance of involving the metal center within the activation process of the PS, reaching values of photosensitivity over 110 times higher than in dark conditions. Moreover, complex 4 promoted apoptotic cell death and possibly the paraptotic pathway, as well as higher ROS generation under irradiation than in dark conditions. Complexes 2–4 accumulated in the mitochondria but species 2 and 4 also localizes in other subcellular organelles. 000151138 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2019-104379RB-C21$$9info:eu-repo/grantAgreement/ES/AEI/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/AEI/RTI2018-097836-J-I00$$9info:eu-repo/grantAgreement/ES/AEI/RYC2018-025872-I$$9info:eu-repo/grantAgreement/ES/DGA-FSE/E07-20R 000151138 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000151138 590__ $$a6.525$$b2021 000151138 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 279 = 0.14$$c2021$$dQ1$$eT1 000151138 592__ $$a0.922$$b2021 000151138 593__ $$aPharmaceutical Science$$c2021$$dQ1 000151138 594__ $$a6.0$$b2021 000151138 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000151138 700__ $$aBenedi A.$$uUniversidad de Zaragoza 000151138 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo I.$$uUniversidad de Zaragoza 000151138 700__ $$0(orcid)0000-0003-0553-0695$$aGimeno M.C. 000151138 700__ $$0(orcid)0000-0002-1218-7218$$aFernández-Moreira V.$$uUniversidad de Zaragoza 000151138 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica 000151138 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000151138 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000151138 773__ $$g13, 9 (2021), 1382 [17 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923 000151138 8564_ $$s4119102$$uhttps://zaguan.unizar.es/record/151138/files/texto_completo.pdf$$yVersión publicada 000151138 8564_ $$s2741009$$uhttps://zaguan.unizar.es/record/151138/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000151138 909CO $$ooai:zaguan.unizar.es:151138$$particulos$$pdriver 000151138 951__ $$a2025-02-27-09:26:02 000151138 980__ $$aARTICLE